

Vice President, Strategic Ventures, Technology & Innovation

Senior Leader in Research Development, Technology Commercialization, Entrepreneurship, Education and Academic Strategic Partnerships

Hands-on **Senior Executive Administrator** and **bridge builder** with demonstrated experience in growing the academic research enterprise and implementing innovative and inclusive programs to foster faculty and student success.

- *Through my leadership, our research funding grew more than 51% (over 5 years) reaching \$275 million in total research expenditures including \$166.4 million in federal funding and \$95 million in NIH awards.*
- *Secured funding and coordinated the launch of the first Institutional Biobank, a Bioscience Accelerator (TechNovum) and several new institutes and centers of research excellence*

EDUCATION

Executive MBA, University of Texas San Antonio, TX

2020-22 (expected)

Ph.D., Evolutionary Biology, University of Catania, Italy, 1992

Master of Science, Natural Sciences, *summa cum laude*, University of Siena, Italy, 1993

Bachelor of Science, Biology, *summa cum laude*, University of Catania, Italy, 1987

LEADERSHIP EXPERIENCE

University of Texas, Health Science Center San Antonio (UTHSCSA), TX

2003 – present

*After joining the UTHSCSA and being promoted to **Full Professor with tenure**, I provided strategic leadership for our Research Mission and built Pipeline and Educational Programs focusing on biosciences, entrepreneurship and innovation, while progressing through roles as **Director of Biomedical Research Development**, **Vice President for Research** and **Vice President for Strategic Industry Ventures**.*

Vice President, Strategic Industry Ventures

2021 - present

- Oversee the Office of Technology Commercialization and provide administrative leadership to advance, disseminate and commercialize UTHSCSA discoveries through the formation of strategic partnerships with industry leaders and the investment community.
- Promote and support entrepreneurial activities of faculty and trainees through educational and professional development programs, formation of new ventures, interaction with the University Accelerator and regional incubators, and assistance with preparation of SBIR/STTR grant proposals.

Vice President for Research

2014 – 2021

Hired as Vice President for Research ad interim in 2014 and confirmed as permanent VPR in 2015. Provided oversight of the institutional research enterprise and strategic planning on multiple levels:

- **Research Infrastructure:** managed and expanded research infrastructure (renovation and extension of animal facility, new institutional research cores and creation of consortia and centers of research excellence).
 - Launched the first Bioscience Accelerator on campus (TechNovum)
 - Raised funds and coordinated design, construction and opening of new research institutes and centers (Barshop Institute for Aging and Longevity Studies, Biggs Institute for Alzheimer and Neurodegenerative Disorders, Stevens Center of Excellence in Parkinson's Disease)
 - Reorganized the governance and assignment of research space
 - Built new IT platforms to streamline the management of basic science and clinical research protocols
 - Increased operational effectiveness of institutional research cores and provided stewardship to philanthropic organizations to create and launch our first Institutional Biobank
- **Research Funding:** Enhanced research funding competitiveness and increased research expenditures through innovative programs matching interdisciplinary research teams, providing seed funding, peer review of grant proposals and incentives to improve the research training environment.
- **Policy & Compliances:** created and updated policies to positively impact the success of faculty, postdocs and trainees; modernized research administration and compliances by developing novel IT platforms to manage clinical trials, conflict of interests, research disclosures, faculty databases, etc.).
- **Executive Leadership:** Provided advocacy for research, chaired the Research Deans Council, and represented the institution with federal/state funding agencies, foundations and corporate research sponsors.
- **Student Engagement:** Worked closely with local philanthropists to develop a 3-year pipeline program targeting high-school students and focusing on hands-on research and professional development activities. Implemented an internship program for undergraduates, graduate students and postdocs to acquire experience in technology transfer and commercialization.
- **Office management:** Had oversight of the following offices and units: Laboratory of Animal Resources (LAR), Office of Clinical Research (OCR), Office of Clinical Trials (OCT), IRB, IACUC, Office of Postdoctoral Affairs (OPA), Institutional Research Core Facilities, Research IT, TechNovum Accelerator, San Antonio Life Science Institute (SALSI), San Antonio Partnership for Precision Therapeutics (SAPPT), Center for Research to Advance Community Health (ReACH), Office of Technology Commercialization (OTC), Barshop Institute for Aging and Longevity Studies, and Biggs Institute for Alzheimer and Neurodegenerative Diseases.

Commitees and Boards (as VP):

- 2018-current - **GRAND Program Committee, Association of American Medical Colleges (AAMC):** Conceptualize and plan the annual GRAND Spring Conference to engage research deans and VPs and advance academic research in a challenging policy and regulatory environment.
- 2018-current - **Executive Leadership Group (Chair), Association Academic Health Centers (AAHC):** The ELG consists of active Vice Presidents for Research who advice the AAHC on policy matters and plan the agenda and content of the AAHC Annual Research Meeting.
- 2018-current - **Board of Directors (Vice Chair), Texas Healthcare & Bioscience Institute (THBI):** THBI is the leading health policy voice in the state of Texas. We work to promote a steady

regulatory environment, create business opportunities for various healthcare entities, and attract new talent in the life sciences

- 2016-current - **Board of Advisors (Member), San Antonio Chamber of Commerce:** Build and sustain San Antonio's business community, military installations, infrastructure, economic development, workforce, and more
- 2014-current - **Board of Directors, BioMedSA:** Promote San Antonio's healthcare and bioscience assets to accelerate regional growth of the sector and enhance San Antonio reputation as a city of science and health
- 2014-current - **Board of Trustees, Texas Research & Technology Foundation (TRTF):** This foundation is a major stakeholder to drive San Antonio economic development around emerging technologies, innovative ventures in bioscience and cybersecurity
- 2015-2021 - **Board of Directors, Texas Society for Biomedical Research (TSBR):** TSBR is a non-profit organization advocating for animal research, and developing "best practices" for the responsible care of animals, and safe use of pathogens and hazardous materials in biomedical research
- 2014-2021 - **Board of Trustees, Texas Biomedical Research Institute (now Texas BioMed).** Provided advice for the continuous improvement of programs, facilities and operations of this research organization, including endowment management, financial investments, election of board members and policy/legislative matters.

Director of Biomedical Research Development

2012 - 2014

Office of the Vice President for Research

- **Managed limited submissions grants** and nomination packets for the President's Scholar Awards and President's Collaborative Research Fund Awards.
- **Reviewed budget and performance of Institutional Organized Research Units**
- **Served as liaison to the UT Office of Federal Relations in Washington DC** to update the VPR on upcoming legislation/policy impacting the research enterprise.
- **Developed a Business Continuity Plan** to ensure the continuity of operations in case of major or catastrophic incidents affecting our campus.
- **Coordinated the organization of the *World Stem Cell Summit***, held in San Antonio, Dec 2014.
- **Advised the VPR** on issues related to the institutional strategic planning and other initiatives including distribution of pilot funds and resources.

ADDITIONAL POSITIONS

AAAS Science & Technology Policy Fellow

2011 - 2012

This was a sabbatical experience to work for a full year in the NIH Office of Science Policy and in the Office of the NINDS Director. My responsibilities included:

- **Research the state of bioinformatics and biomedical computing networks** to manage large biomedical datasets, predict toxicity and efficacy of biomedical products, and promote personalized medicine.
- **Collect information on NIH-FDA cross-training activities and fellowships**, and analyze NIH grant portfolios on innovative clinical trial design.
- **Review FDA regulations** on companion diagnostic devices and other biomedical products to identify challenges and develop comments reflecting the viewpoints of NIH and its stakeholders.
- **Develop agendas and talking points for the NIH-FDA Joint Leadership Council** and holding meetings with senior NIH and FDA staff to discuss and promote interagency personnel exchanges and collaborations.

- **Answer questions for the Congressional Record (QFRs)** on topics related to NIH programs, regulatory science and drug development.
- **Wrote the Chapter on Neuroscience Research of the Biannual Progress Report of the NIH** research portfolio presented to the US Congress.

President, San Antonio Chapter of the Society for Neuroscience (SfN) 2008-2010

Supervised and expanded outreach activities of the SfN local chapter to educate the public on societal implications of neuroscience research and coordinated travel awards for graduate students and postdocs to present at the SfN annual meeting.

ACADEMIC POSITIONS

Department of Pharmacology, UTHSCSA, San Antonio, TX	2003 - present
<i>Professor with Tenure</i>	2015 - present
<i>Associate Professor with Tenure</i>	2010 - 2015
<i>Assistant Professor</i>	2003 - 2010
Department of Pharmacology, University of California, Irvine, CA	1988 - 2003
<i>Assistant Adjunct Professor</i>	2001 - 2003
<i>Assistant Specialist</i>	1998 - 2001

POST-DOCTORAL EXPERIENCES

Postdoctoral Fellow , The Neurosciences Institute, San Diego, CA	1997 - 1998
Visiting Scientist , Inst. of Reproductive Medicine, University of Hannover, Germany	1994 - 1995
Postdoctoral Fellow , Dept. of Evolutionary Biology, University of Siena, Italy	1993 - 1996

AWARDS & HONORS

Distinguished Graduate Student Award, College of Business, University of Texas SA	2021
Board of Directors (Vice Chair), Texas Healthcare & Bioscience Institute	2018
Board of Directors (Member), BioMedSA	2015
Board of Trustees (Special trustee), Texas Biomedical Research Institute	2014
Board of Trustees (Trustee), Texas Research & Technology Foundation	2014
AAAS Science & Technology Policy Fellow	2011
Council of Academic Societies (member), Association of American Medical Colleges	2009
Society for Neuroscience Chapter Award	2009
Faculty Career Development Award, University of California Irvine	1999
Fellowship for Specialized Studies Abroad, University of Siena, Italy	1994

RESEARCH FUNDING (completed)

2017-19	W. & E. Owens Research Foundation, "Role of Traumatic brain injury in the development of Parkinson's disease" (sole PI)
2011-17	R01 MH091130 - Endocannabinoid Transmission in Schizophrenia (PI)
2015-16	UT System - UTSA/UTEP/UTHSCSA Technology Entrepreneurship and Commercialization (TEC) Partnership" (co-PI)
2013-15	SBIR MH101892 - Discovery of novel antipsychotics through quantum similarity (co-PI)
2013-15	Stevens Foundation - Role of neuroinflammation in the development of L-DOPA-induced dyskinesias (PI)
2004-14	R01 NS050401 - Role of endocannabinoids in L-DOPA-induced dyskinesias (PI)
2009-14	R01 DA019222 -Treatment of cannabinoid withdrawal in Rhesus Monkeys (co-PI)
2012-13	Center for Innovation in Drug Discovery, Pilot Project Award (PI)
2010-12	Michael J. Fox Foundation, Target Validation Grant (PI)
2010-11	San Antonio Area Foundation, Grant Contract (PI)
2008-09	National Parkinson Foundation (NPF), Research Grant (PI)
2008-11	National Science Foundation (NSF), Research Grant (co-PI, subcontract)
2007-09	NARSAD, Young Investigator Award (PI)
2007-08	American Parkinson's Disease Association (APDA), Research Grant (PI)
2006-07	University Research Committee Award (Pilot grant), UTHSCSA (PI)
2004-05	Executive Research Committee Award (Pilot grant), UTHSCSA (PI)
2001-02	Parkinson's Disease Foundation, International Research Grant Award (PI)
2001-02	College of Medicine Committee Research Award, UC Irvine (PI)

FUNDING (current)

1. P. & R. Stevens Foundation, "Accelerating PD research: the Perry & Ruby Stevens Parkinson's Disease Center of Excellence" (PI), \$ 300,000/year (July 2017- June 2022).
2. Max and Minnie Tomerlin Voelcker Fund Grant, "Biomedical Research Academy" (sole PI) \$240,000/year (Jun 2020-May 2024)

PROFESSIONAL MEMBERSHIPS

2018-present Association of American Medical Colleges (AAMC), GRAND Program Committee

2018-present Association of Academic Health Centers (AAHC), Executive Leadership Group (Chair)
 2016-present Society of Research Administrators International (SRA)
 2014-present Network of Academic Corporate Relations Officers (NACRO)
 2012-present Association of University Technology Managers (AUTM)
 2000-present Society for Neuroscience (SfN)
 2008-present International Neuroethics Society, Member
 2000-present American Association for the Advancement of Science (AAAS), Member
 1998-present Cannabinoid Research Society (CRS)
 2000-2010 American Society for Pharmacology and Experimental Therapeutics (ASPET)

INVITED PRESENTATIONS (highlights)

02-25-22 "Pathways to Careers in Science" (Panelist). Office of Postdoctoral Affairs Series. UT Health San Antonio, TX

01-25-22 "Global Collaborations and Research Partnerships" (Panel Chair). 2022 AAHC Research Forum.

09-29-21 "How will Academic Health Centers Prepare for Future Pandemics" (Panelist). 2021 AAHC Annual Meeting.

11-30-20 "Early Arrivals" session (Panel Coordinator), 2020 Research Meeting of the Association of Academic Health Centers (AAHC).

07-30-20 "Artificial Intelligence applications in biomedical research at UT Health San Antonio". MATRIX AI Consortium meeting, UTSA, San Antonio, TX.

12-2019 "How Can AHCs Meet the Needs of Translational Scientists Through a Life-Science Accelerator Program?". 2019 Research Meeting of the Association of Academic Health Centers (AAHC), Washington, DC.

11-2019 "Overview of Nursing Reserch at UTHealth San Antonio". Texas Healthcare & Bioscience Institute Roundtable, San Antonio, TX.

11-2018 "Ownership of ideas and power dynamics in Academia". Panel: "Recognizing and Addressing Power Dynamics in Science and Academia". Society for Neuroscience 2018, San Diego, CA.

09-2018 "The difficult job of postdocs: take charge of your career!" (Keynote Speaker). 6th Postdoctoral Research Forum, San Antonio, TX.

06-2018 "Drugs in the brain: therapy vs. enhancement". Mikiten Research Symposium, San Antonio, TX.

11-2017 "UT Health SA: Pioneering innovation for Texas and beyond" – Panel: "Innovation in Research and Healthcare", 2017 Fall Policy Summit, Texas Healthcare & Bioscience Institute, Texas Capitol Austin, TX.

03-2017 "Medical use of cannabinoids" (Instructor). Short course, Dept. of Molecular Neuroscience, Anahuac Mayab University, Merida, Mexico.

- 10-2016 "Research, Innovation and Impact: Developing an Institutional Research Strategy for the Future and for Implementation". Society of Research Administrators (SRA) International: Senior Executive Institute, Annual meeting, San Antonio, TX
- 07-2016 "Neurodegenerative diseases: from bench to bedside". 2016 Aging in Texas Conference, San Antonio, TX
- 03-2016 "Research and science policy". Science Fiesta 2016. San Antonio, TX.
- 01-2016 "Best practices in communication and transparency". Discovery Leadership Council, University of Texas System. Austin, TX.
- 03-2015 "Creating the future of Biomedical Research: UTHSCSA report". AAMC GRAND Spring Conference. Washington, DC.
- 03-2015 "What clinicians and non-clinicians need in devices, drug discovery and data analytics". (Panel Chair). SALSI Academy Innovation Forum. San Antonio, TX.
- 03-2015 "Pathways to careers in science" (Panel Chair). 2015 Behavior, Biology, and Chemistry Conference, San Antonio, TX..
- 10-2014 "The ABC's of the endocannabinoid system". Child Neurology Society, 43rd Annual Meeting, Columbus, OH.
- 05-2014 "Cannabinoids, endocannabinoids and schizophrenia: from risk factor to therapy". Grand Rounds Series. Department of Psychiatry, UTHSCSA.
- 04-2014 "Endocannabinoid-enhancing drugs reverse social withdrawal in the PCP rat model of schizophrenia" (Panel Chair). 4th Schizophrenia International Research Society Conference, Florence, Italy.
- 04-2014 "Endocannabinoid identification and quantification in biological samples". Department of Pharmacy, University of Naples "Federico II", Italy.
- 03-2014 "Pathways to careers in science" (Panel Chair). 2014 Behavior, Biology, and Chemistry Conference, San Antonio.
- 02-2014 "The cannabinoid hypothesis of schizophrenia". Seminars in Translational Research (STRECH seminar series), University of Texas San Antonio, San Antonio, TX.
- 10-2013 "The aftermath of an AAAS Science & Technology Policy Fellowship: add value and reshape your career" (Panel Chair). TMOB seminar series. UTHSCSA, San Antonio, TX.
- 10-2013 "Linking science and policy to increase innovation and leadership in STEM". Panel Briefing, Annual SACNAS National Conference, San Antonio, TX.
- 06-2013 "Targeting PPAR for the treatment of L-DOPA-induced dyskinesias". 2nd International Conference on Neurology and Therapeutics, Chicago, IL.
- 04-2013 "Cannabinoid targets in psychomotor disorders: new therapeutic approaches", Trinity University, San Antonio, TX.
- 03-2013 "Is NIH on the verge of a (fiscal) cliff?" Science Communication Seminar Series. UTHSCSA, San Antonio, TX.

- 12-2012 “Activation of PPARgamma receptor reduces levodopa-induced dyskinesias in an animal model of Parkinson’s disease” (Panel Chair). 8th Conference of Italian researchers in the World, Houston, TX.
- 10-2012 “New insights on endocannabinoid transmission in psychomotor disorders”. Dept. of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Italy.
- 06-2012 “Insights in Neuroethics”. Dept. of Bioethics, NIH Clinical Center, Bethesda, MD.
- 07- 2011 “Endocannabinoid transmission: role in neurodegeneration and schizophrenia” (Panel Chair). 8th IBRO World Congress of Neuroscience, Florence, Italy.
- 04- 2011 “Targeting conventional and non-conventional cannabinoid receptors for the treatment of Parkinson’s disease”, Dept. Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX.
- 03-2011 “Conventional and non-conventional cannabinoid targets for CNS disorders”, 42nd Annual Meeting American Society Neurochemistry, St. Louis, MO.
- 02-2011 “Cannabinoid receptors in dopamine-related disorders”, Dept. of Neuroscience, Thomas Jefferson University, Philadelphia, PA.
- 01-2011 “Neuroethics: brain, mind and new challenges”, UTHSCSA, San Antonio, TX.
- 03-2010 “Cannabinoid and endocannabinoid targets in Parkinson’s disease”, Dept. of Neuroscience & Cell Biology, University of Texas Medical Branch, Galveston, TX.
- 08-2009 “Cannabinoid and PPAR receptors are therapeutic targets for the treatment of levodopa-induced dyskinesias”, 7th Annual International Congress Drug Discovery S&T, Shanghai, China.

SERVICE

- 2020-current **UTHSA Diversity, Equity & Inclusion Council**: create strategic plans and goals to advance and advocate for equity, diversity and inclusion across all areas of the University, review best practices and submit recommendations to the President.
- 2020-current **MassChallenge Global Program, Judge**: review startup applications for the MassChallenge 2020 competition helping entrepreneurs from more than 54 countries to launch and grow new businesses.
- 2018-current **Advisory Board (Member), Biggs Institute for AD and Neurodegenerative Diseases (UTHSCSA)**: Formally advise the Institute’s leadership on strategic goals, recruitments and future expansion plans.
- 2016-19 **Steering Committee (Member), Biomedical Research Administration Development (BRAD) grant**: Advised and developed a strategic plan to increase research capacity and infrastructure at St Mary’s University (San Antonio).
- 2016-18 **Special Advisor to the Dean of the School of Dentistry (UTHSCSA)**: Assisted the Dean to recruit the Associate Dean for Research, and conceptualized the job description, infrastructure and operations of the Research Office in the School of Dentistry.

- 2015-present **UTHSCSA Compliance & Ethics Committee (Member)**. Ensure appropriate compliance policies, procedures and practices for various institutional activities. Identify mechanisms for communicating compliance issues, develop appropriate training for our employees and participate in investigations conducted by the Office of Regulatory Affairs and Compliance.
- 2013-15 **Advisory Board Member, UT System FreshAIR**. This strategic initiative from the University of Texas System promoted the creation of partnerships between pharmaceutical/biotech companies and UT Health Institutions. Participated in the strategic planning of the first Research Forum and selected speakers and poster presentations to showcase our institutional intellectual property.
- 2010-14 **International Neuroethics Society (Communication & Outreach Committee Member)**. Contributed to the planning of the Annual Meeting of the Neuroethics Society and developed new initiatives to foster education on the ethical and societal implications of neuroscience research.
- 2009-11 **Member of Innovation Task Force, AAMC Council of Academic Societies**. Served as a consultant on critical issues, such as aligning priorities and missions in academic medicine, faculty reward, new business models for medical schools, etc.

STUDY SECTIONS

- 2014-present Qatar National Research Fund Study Section (external reviewer)
- 2013-2018 NIH SBIR/STTR ETTN-M 11 Study Section
- 2012-2018 Ricerca Finalizzata (Italian Ministry of University) (external reviewer)
- 2013 ANR (French National Agency for Research) (external reviewer)
- 2012 Czech Science Foundation (external reviewer)
- 2008 PRIN Projects (Italian Ministry of University) (external reviewer)
- 2004 Philips Morris External Research Program (external reviewer)

UNIVERSITY COMMITTEES

- 2021-present Interprofessional Education Committee (Member)
- 2020-present Diversity, Equity & Inclusion Council
- 2014-present Endowment Compliance Committee (Member)
- 2019-2021 Task Force on Foreign Influence (Chair)
- 2019-2021 Research Deans' Council (Chair)
- 2018-2020 Committee on Organizational Effectiveness (Member)
- 2014-2019 Research Strategic Advisory Council (Chair)
- 2014-18 South Texas Research Facility Council (Chair)
- 2014-17 Executive Committee on Space Management (Member)
- 2012-16 Post Tenure Evaluation Committee (Member)
- 2012-15 Promotion, Tenure, Appointment Committee (Member)
- 2008-15 Neuroscience Student Oversight Committee (Member)
- 2008-15 Neuroscience Track Executive Committee (Member)
- 2008-14 Neuroscience Track (Co-leader)
- 2008-11 Neuroscience Student Oversight Committee (Chair)
- 2007-10 IMPG Graduate Student Admission Committee (Member)
- 2007-08 Cross/Adjunct/Research Track Appointment Committee (Chair)
- 2005-09 Committee on Graduate Studies (Member)

STUDENT SUPERVISING COMMITTEES

2018-21	Dissertation committee: Ahsan Choudari (PhD candidate, primary mentor UTHSCSA)
2016-19	Dissertation committee: Antony Martinez (PhD candidate, UTHSCSA)
2013-16	Dissertation committee: David Aguilar (PhD candidate, UTHSCSA)
2011-14	Dissertation committee: Stephanie Perez (PhD candidate, UTHSCSA)
2011-14	Dissertation committee: Bai Xiang (Vicky) (PhD candidate, UTHSCSA)
2005-12	Dissertation committee: Margaret Wei, Alexandra Soto-Pina, Jennifer Stewart, Niki Ruparel, Alex Martinez (PhD Candidates, UTHSCSA)
2004-07	Dissertation committee: David Price; Mona Bains; Anibal Diogenes (PhD candidates, UTHSCSA)
2004	Neuroscience Student Mentoring Committee (Chair)

EDITORIAL SERVICES

2014-present	International Journal of Neuropsychopharmacology (Editorial Board, member)
2012-present	Pharmaceutical Regulatory Affairs: open access (Editorial Board, member)
2009-13	International Journal of Neuropsychopharmacology (Guest Field Editor)

Invited Referee:

Behavioral Brain Research
 Biochimica Biophysica Acta
 Biological Psychiatry
 Brain Research
 British Journal of Pharmacology
 Clinical Biochemistry
 Glia
 Hippocampus
 International Journal of Neuropsychopharmacology
 Journal of Biological Chemistry
 Journal of Neuroscience
 Journal of Neurochemistry
 Journal of Pharmacology and Experimental Therapeutics
 Molecular Brain Research
 Nature Neuroscience
 Nature Reviews Neuroscience
 Neuropsychopharmacology
 Neuropharmacology
 Neurobiology of Disease
 Pharmacology Biochemistry and Behavior
 PlosOne
 Synapse

TEACHING

New courses created to address educational needs at our institution:

- 1) **Basics of Research Design** – This course focuses on experimental design and science communication to orient students in setting up scientific experiments, writing grant proposals and manuscripts and preparing for the qualifying exams.
- 2) **Fundamentals of Neuroethics** – This is the only course at our institution addressing the ethical, philosophical and social implications of neuroscience research.
- 3) **Topics in Translational Medical Product Development** – This course covers practices and regulatory requirements necessary for the development of biomedical products (therapeutics,

biologics and medical devices), as well as concepts relative to intellectual property, commercialization and business plan development.

Teaching activities

- 2011-present “Fundamentals of Neuroethics”. Elective for PhD students in Neuroscience. IMGP. UTHSCSA (**Course director**).
- 2014-present “Responsible Conduct of Research”. Course for medical and graduate students. UTHSCSA.
- 2014-18 “Topics in Translational Medical Product Development”. Elective for IMGP graduate students. UTHSCSA (**Course director**).
- 2013-16 “Neurotechnologies: engineering the brain”. Lecture for START-UP students.
- 2013-14 “Alternative careers in science”. Professional development chalk talk for R25 students.
- 2010-11 “Unconventional Neurotransmitters”. Molecular Neuroscience Course for IMGP PhD students in Neuroscience. UTHSCSA.
- 2007-10 “Neuroanatomy”. Course for IMGP PhD students in Pharmacology. UTHSCSA.
- 2006-14 “Basics of Research Design”. Course for IMGP Ph.D. students in Pharmacology. UTHSCSA (**Course director**).
- 2004-11 “Phospholipases and Lipid signaling”. Principles of Pharmacology. Course for IMGP PhD students in Pharmacology. UTHSCSA.
- 2003 “Drugs of abuse”. Neurotransmitter and Drug Receptors Course for medical students. UC Irvine, CA.
- 2002 “Lipids as signaling molecules”. Neurotransmitter and Drug Receptors Course for PhD students in Pharmacology. UC Irvine, CA.
- 2001 “Novel lipid-derived mediators”. Medical Pharmacology Course for PhD students in Pharmacology. UC Irvine, CA.
- 2001 “Excitatory amino acids and “Peptidergic systems”. Chemical Neuroanatomy Course for PhD students in Pharmacology. UC Irvine, CA.
- 2001 “LC/MS analysis of lipids”. Methods in Pharmacology Course for PhD students in Pharmacology. UC Irvine, CA.
- 1996 “Origin of life and evolution of eukaryotic cell”. Undergraduate seminar (Teaching assistant). University of Siena, Italy.
- 1990-96 “Citology and Histology”. Courses for undergraduate and graduate students, Universities of Siena and Catania, Italy.

PUBLICATIONS

Peer-reviewed Articles:

1. **Giuffrida A.** Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. In: *Endocannabinoid regulation of monoamines in psychiatric and neurological disorders* (Van Bocksteale E., ed), Springer. (2022, in press).
2. Differential effects of $\Delta 9$ -tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model, *PLoS One* 12: 15 (2020). PMID: 32163506
3. Seillier A., **Giuffrida A.** Differential effects of $\Delta 9$ -tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model, *PLoS One* 12: 15 (2020). PMID: 32163506.
4. Perez S., Donegan J.J., Boley A.M., Aguilar D.D., **Giuffrida A.**, Lodge D.J. Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces schizophrenia-like phenotype in the rat. *Schizophrenia Res.* 206: 263-270 (2019). PMID: 30522798.

5. Aguilar D.D, **Giuffrida A.**, Lodge D.J. Adolescent synthetic cannabinoid exposure produces enduring changes in dopamine neuron activity in a rodent model of schizophrenia susceptibility. *Int. J. Neuropsychopharmacol.* 21: 393-403 (2018). PMID: 29329382
6. Seillier A., **Giuffrida A.** The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: further evidence for transporter-mediated endocannabinoid release. *Neuropharmacology* 130: 1-9 (2018). PMID: 29169961
7. Seillier A., **Giuffrida A.** Anxiety does not contribute to social withdrawal in the sub-chronic PCP rat model of schizophrenia. *Behav. Pharmacol.* 28: 512-520 (2017). PMID: 28704273
8. Wang J., **Giuffrida A.** The development of medical devices in foreign markets. *Pharmaceutical Regulatory Affairs.* 5:2 (2016) DOI: 10.4172/2167-7689.1000167.
9. Seillier A., **Giuffrida A.** Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: possible involvement of the endocannabinoid system. *Eur. Neuropsychopharmacol.* 26: 298-309 (2016). PMID: 26706691
10. Mulas G., Espa E., Cossu G., Fenu S., Pillai E., Angius F., Spolittu S., Batetta B., Spiga S., Lecca D., Carboni E., Jadžić D., Simbula G., **Giuffrida A.**, Carta A. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease. *Exp. Neurol.* 286: 83-92 (2016). PMID: 27697481
11. Matricon J., Seillier A., **Giuffrida A.** Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. *Neurosci. Res.* 110: 49-58 (2016). PMID: 27091613
12. Aguilar D.D., **Giuffrida A.**, Lodge D.J. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. *J. Psychopharmacol.* 30: 169-181 (2016). PMID: 26510449
13. Perez S., Aguilar D., Neary J., Carless M., **Giuffrida A.**, Lodge D. Schizophrenia-like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia. *Neuropsychopharmacology* 41: 477-486 (2016). PMID: 26068729
14. Bilbao A., Serrano A., Cippitelli A., Pavon F. J., **Giuffrida A.**, Suárez J., Garcia-Marchena N., Baixeras E., Gómez de Heras R., Alen F., Orio L., Cravatt B., Parsons L., Ciccocioppo R., Piomelli D., Rodríguez de Fonseca F. Role of the Satiety Factor Oleoylethanolamide in Alcoholism. *Addiction Biol.* 21: 859-872 (2016). PMID: 26037332
15. Hrubá L., Seillier A., Zaki A., Cravatt B.F., Lichtman A.H., **Giuffrida A.**, McMahon L.R. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ^9 -tetrahydrocannabinol in mice. *J. Pharmacol. Exp. Ther.* 353: 261-268 (2015). PMID: 25711338
16. Martinez A.A, Morgese M.G., Pisanu A., Macheda T., Paquette M.A., Seillier A., Cassano T., Carta A., **Giuffrida A.** Activation of PPAR γ receptors alleviates levodopa-induced dyskinesia in 6-OHDA-treated rats. *Neurobiol Dis.* 74: 295-304 (2015). PMID: 25486547
17. Sanchez Lopez A.J., Roman-Vega L., Ramil Tojero E., **Giuffrida A.**, Garcia-Merino A. Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon- β : a longitudinal study in multiple sclerosis patients. *Clin. Exp. Immunol.* 179: 119-127 (2015). PMID: 25169051

18. Seillier A., Aguilar D.D., **Giuffrida A.** The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184. *Pharmacol. Biochem. Behav.* 124: 153-159 (2014). PMID 24911644
19. Seillier A., Martinez AA, **Giuffrida A.** Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors. *Neuropsychopharmacology* 38: 1816-1824 (2013). PMID: 23563893
20. Raichlen D.A., Foster A.D., Seillier A., **Giuffrida A.**, Gerdeman G.L. Exercise-induced endocannabinoid signaling is modulated by intensity. *Eur. J. Appl. Physiol.* 113: 869-75 (2013). PMID: 22990628
21. Denora N., Cassano T., Laquintana V., Lopalco A., Trapani A., Cimmino C.S., Laconca L., **Giuffrida A.**, Trapani G. Novel codrugs with GABAergic activity for dopamine delivery in the brain. *Int. J. Pharm.*, 437: 221-231 (2012). PMID: 22940209
22. Paquette M.A., Martinez A.A., Macheda T., Meshul C.K., Johnson S.W., Berger S.P., **Giuffrida A.** Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. *Eur. J. Neurosci.* 36: 3224-3234 (2012). PMID: 22861201
23. Martinez AA, Macheda T, Morgese MG, Trabace L, **Giuffrida A.** The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. *Neurosci Res.* 72: 236-242 (2012). PMID: 22192465
24. Gould GG, Seillier A, Weiss G, **Giuffrida A.**, et al., Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. *Progress Neuropsychopharmacol. Biol. Psychiatry* 38: 260-269 (2012). PMID: 22542870
25. Raichlen DA, Foster AD, Gerdeman GL, Seillier A, **Giuffrida A.** Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. *J Exp Biol.* 215:1331-1336 (2012). PMID: 22990628
26. Seillier A., **Giuffrida A.** Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats. *Pharmacol. Biochem Behav.* 98: 583-586 (2011). PMID: 21421000
27. Cunningham R.L., Macheda T., Talley Watts L., Poteet E., Singh M., Roberts J.L., **Giuffrida A.** Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. *Hormones & Behavior* 60: 617-624 (2011). PMID: 21907204
28. Solbrig M., Fan Y., Hermanowicz N., Morgese M., **Giuffrida A.** A synthetic cannabinoid agonist promotes oligodendroglialogenesis during viral encephalitis in rats. *Exp. Neurol.*, 226: 231–241 (2010). PMID: 20832403
29. Seillier A., Advani T., Cassano T., Hensler J.G., **Giuffrida A.** Inhibition of fatty acid amide hydrolase and CB1 receptor antagonism differentially affect behavioral responses in normal and PCP-treated rats. *Int. J. Neuropsychopharmacol.* 13: 373-386 (2010). PMID: 19607756
30. Cunningham R.L., **Giuffrida A.**, Roberts J. L. Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of PKCdelta. *Endocrinology* 150:5539-5548 (2009). PMID: 19837873

31. Price D.A., Martinez A.A., Seillier A., Koek W., Acosta Y., Fernandez E., Strong R., Lutz B., Marsicano G., Roberts J.L., **Giuffrida A.** WIN55212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the MPTP mouse model of Parkinson's disease. *Eur. J. Neurosci.* 29: 2177-2186 (2009). PMID: 19490092
32. Seillier A, **Giuffrida A.** Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. *Behav. Brain Res.* 204: 410-415 (2009). PMID: 19716985
33. Morgese M, Cassano T, Gaetani S, Macheda T, La Conca L, Di Pasquale P., Ferraro L, Antonelli T, Cuomo V., **Giuffrida A.** Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55212-2. *Neurochem Int.* 54: 56-64 (2009). PMID: 19010365
34. Koethe D., Schreiber D, **Giuffrida A.**, Mauss C, Faulhaber J, Heydenreich B, Hellmich M, Klosterkötter J, Piomelli D, Leweke FM. Sleep deprivation increases oleylethanolamide in human cerebrospinal fluid. *J. Neural Transm.* 116: 301-305 (2009). PMID: 19137236
35. Koethe D, **Giuffrida A.**, Schreiber D, Gross S, Hellmich M, Schultze-Lutter F, Klosterkötter J, Piomelli D, Leweke FM. Anandamide elevation in CSF of prodromal states of schizophrenia. *Br. J. Psychiatry* 194: 371-372 (2009). PMID: 19336792
36. Morgese M, Cassano T, Cuomo V., **Giuffrida A.** Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB1 and TRPV1 receptor receptors. *Exp. Neurol.* 208: 110-119 (2007). PMID: 17900568
37. Leweke F.M., **Giuffrida A.**, Koethe D., Schreiber D., Nolden B.M., Neatby N.A., Schneider M., Gerth C., Klosterkoetter J., Piomelli D. Anandamide levels in CSF of first-episode schizophrenic patients: impact of cannabis use. *Schizophrenia Res.* 94: 29-36 (2007). PMID: 17566707
38. Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, **Giuffrida A.**, Serrano A, Baixeras E, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F. Regulation of brain anandamide by acute administration of ethanol. *Biochem J.* 404: 97-104 (2007). PMID: 17302558
39. Price D.A., Owens W.A., Gould G.G., Frazer A., Roberts J.L., Daws L.C., **Giuffrida A.** CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. *J. Neurochem.* 101: 389-396 (2007). PMID 19490092.
40. Schreiber D., Barlfinger S., Nolden B.M., Gerth C.W., Jaehde U., Schoemig E., Klosterkoetter J., **Giuffrida A.**, Astarita G., Piomelli D., Leweke F.M. Determination of anandamide and other fatty acid ethanolamides in human serum by electrospray tandem mass spectrometry. *Anal. Biochem.* 361: 162-168 (2007). PMID: 17196922
41. Hardison S., Weintraub S, **Giuffrida A.** Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. *Prostagland. Lipid Mediators* 81:106-112 (2006). PMID: 17085319
42. **Giuffrida A.**, Price D.A., Daws L.C., Owens W.A., Gould G.G., Frazer A., Seillier A., Roberts J.L.. Inhibition of dopamine transporter activity by cannabinoids. *Neuropsychopharmacology*, 30: S133 (2005). PMID: 17250681
43. Solbrig M.V., Adrian R., Baratta J., Piomelli D., **Giuffrida A.** A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. *Exp. Neurol.*, 194: 355-362 (2005). PMID: 16022863

44. McPartland J.M., **Giuffrida A.**, King J., Skinner E., Scotter J., Musty R.E. Cannabimimetic effects of osteopathic manipulation. *J. Am. Osteopath. Assoc.* 283-291 (2005). PMID: 16118355
45. **Giuffrida A.**, Leweke F.M., Gerth C.W., Fegley, D., Faulhaber, J., Klosterkoetter J., Valino F., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology* 29: 2108-2114 (2004). PMID: 15354183
46. Ferrer B., Asbrock N., Kathuria S., Piomelli D., **Giuffrida A.** Effects of levodopa on endocannabinoid signaling in the basal ganglia: implications for the treatment of levodopa-induced dyskinesias. *Eur. J. Neurosci.* 18: 1607-1614 (2003). PMID: 14511339
47. Sparling, P.B., **Giuffrida A.**, Piomelli D., Rosskopf L., Dietrich A. Exercise activates the endocannabinoid system. *Neuroreport* 14: 2209-2211 (2003). PMID: 14625449
48. Schaebitz W.R., **Giuffrida A.**, Berger G., Aschoff A., Schwaninger M., Schwab S., Piomelli D. Release of fatty acid amides in a patient with hemispheric stroke. *Stroke* 33: 2112-2114 (2002). PMID: 12154273
49. Schuel H., Burkman L.J., Lippes J., Crickard K., Mahony M.C., **Giuffrida A.**, Picone R.P., Makriyannis A. Evidence that anandamide-signaling regulates human sperm functions required for fertilization. *Mol. Reprod. Dev.* 63: 376-387 (2002). PMID: 12237954
50. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., **Giuffrida A.**, Lo Verme J., Gaetani S., Gall C., Piomelli D. An anorexic lipid regulated by feeding. *Nature* 414: 209-212 (2001). PMID: 11700558
51. **Giuffrida A.**, Rodriguez de Fonseca F., Nava F., Loubet-Lescoulie P., Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. *Eur. J. Pharmacol.* 408: 161-168 (2000). PMID: 11080522
52. Calignano A., Katona I., Desarnaud F., **Giuffrida A.**, La Rana G., Mackie K., Freund T.F., Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. *Nature*, 408: 96-101 (2000). PMID: 11081515
53. **Giuffrida A.**, Rodriguez de Fonseca F., Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. *Anal. Biochem.* 280: 87-93 (2000). PMID: 10805525
54. Beltramo M., Rodriguez de Fonseca F., Navarro M., Calignano A., Gorriti M.A., Grammatikopoulos G., Sadile A.G., **Giuffrida A.**, Piomelli D. reversal of dopamine D2-receptor responses by an anandamide transport inhibitor. *J. Neurosci.* 20: 3401-3407 (2000). PMID: 10777802
55. **Giuffrida A.**, Parsons L.H., Kerr T.M., Rodríguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nature Neuroscience* 2: 358-363 (1999). PMID: 10204543
56. Leweke F.M., **Giuffrida A.**, Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. *NeuroReport* 10: 1665-1669 (1999). PMID: 10501554
57. Calignano A., La Rana G., **Giuffrida A.**, Piomelli D. - Control of pain initiation by endogenous cannabinoids. *Nature* , 394: 277-281 (1998). PMID: 9685157
58. **Giuffrida A.**, Piomelli D. - Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. *FEBS Lett.*, 422: 373-376 (1998). PMID: 9498819

59. Focarelli R., **Giuffrida A.**, Capparelli S, Scibona M, Menchini Fabris F., Francavilla F., Francavilla S., Della Giovampaola C., Rosati F. - Specific localization in the equatorial region of gp20, a 20-kDa sialylglycoprotein of the capacitated human sperm acquired during epididymal transit and necessary to penetrate zona-free hamster eggs. *Molec. Hum. Reprod.*, 4: 119-125 (1998). PMID: 9542968
60. **Giuffrida A.**, Focarelli R., Lampariello R., Rosati F. Glycan chains play a role in the axonemal cytoskeleton disassembly activity of the 35 kDa glycoprotein of the spermathecal extract of *Eyrepocnemis plorans* (Insecta, Orthoptera). *Insect Biochem. Molec. Biol.*, 27: 315-321 (1997).
61. **Giuffrida A.**, Focarelli R., Lampariello R., Thole H., Rosati F. - Purification and properties of a 35 kD glycoprotein from spermathecal extract of *Eyrepocnemis plorans* (Insecta, Orthoptera) with axonemal cytoskeleton disassembly activity. *Insect Biochem. Molec. Biol.*, 26: 347-354 (1996).
62. Focarelli R., **Giuffrida A.**, Rosati F. Changes in the sialylglycoconjugate distribution on the human sperm surface during in-vitro capacitation: partial purification of a 20kD sialylglycoprotein of capacitated spermatozoa. *Hum. Repr.*, 10: 2755-2759 (1995). PMID: 8567809
63. Longo G., Sottile L., Viscuso R., **Giuffrida A.**, Privitera R. Ultrastructural changes in sperm of *Eyrepocnemis plorans* (Chapentier) (Orthoptera: Acrididae) during storage of gametes in female genital tract. *Invert. Reprod. Dev.*, 24: 1-6 (1993).
64. **Giuffrida A.**, Rosati F. - Changes in sperm tail of *Eyrepocnemis plorans* as a result of *in vitro* incubation in spermathecal extract. *Invert. Reprod. Dev.*, 24: 47-52 (1993).
65. Viscuso R., **Giuffrida A.**, Longo G. - Ultrastructural rearrangements of the vitelline envelope during egg development in *Eyrepocnemis plorans* (Charp.) (Orthoptera: Acrididae). *Boll. Zool.*, 59: 239-243. (1992).
66. **Giuffrida A.** - Connecting flagellar elements in the sperm of *Eyrepocnemis plorans* (Charp.) (Orthoptera: Acrididae). *Int. J. Insect Morphol. Embryol.*, 20: 319-322. (1991).
67. Longo G., Viscuso R., Sottile L., **Giuffrida A.** Lectin binding to the egg envelopes in *Eyrepocnemis plorans* (Charp.) (Orthoptera, Acrididae). *Bas. Appl. Histochem.*, 34: 127-134. (1990).

Reviews (Peer Reviewed)

65. **Giuffrida A.**, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. *Progress in Neuro-Psychopharmacol. Biol Psychiatr.* 38:51-8 (2012). PMID: 22521335
66. **Giuffrida A.** McMahon L.R., In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. *Prostag. Lipid Mess* 91: 90-103 (2010). PMID: 19523530
67. Schuel H., Burkman L.J., Lippes J., Crickard K., Forester E., Piomelli D., **Giuffrida A.** N-acylethanolamines in human reproductive fluids. *Chem. Phys. Lipids.* 121: 211-227 (2002). PMID: 12505702
68. **Giuffrida A.**, Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. *J. Pharmacol. Exp. Ther.* 298: 7-14 (2001). PMID: 11408519
69. Piomelli D., **Giuffrida A.**, Calignano A., Rodriguez de Fonseca F. The endogenous cannabinoid system as a target for therapeutic drugs. *TIPS* 21:218-224 (2000). PMID: 10838609

70. **Giuffrida A.**, Desarnaud F., Piomelli D. Endogenous cannabinoid signaling and psychomotor disorders. *Prostaglandins Lipid Mediators* 61: 63-70 (2000). PMID: 10785542
71. **Giuffrida A.**, Piomelli D. The endocannabinoid system: a physiological perspective on its role in psychomotor control. *Chem. Phys. Lipids* 108: 151-158 (2000). PMID: 11106788
72. Piomelli D., Beltramo M., **Giuffrida A.**, Stella N. Endogenous cannabinoid signalling. *Neurobiology of Disease*, 5: 462-473 (1998). PMID: 9974178

Book chapters and other Publications

73. **Giuffrida A.**, Gray J. Ownership of Ideas and Power Dynamics in Academia. In: Recognizing and Addressing Power Dynamics in Science and Academia. (Giuffrida A, Marín-Spiotta E, King J, eds) Washington, DC: Society for Neuroscience (2019).
74. **Giuffrida A.** Parkinson's disease and the endocannabinoid system. In: *The Endocannabinoid System: Genetics, Biochemistry, Brain disorders and Therapy* (Murillo-Rodriguez, ed.), Elsevier, pp. 236 (2017).
75. Sifuentes M.M., **Giuffrida A.** Drug review differences across the United States and the European Union. *Pharmaceut. Reg. Affairs* 4: 4 (2015).
76. **Giuffrida A.**, Martinez A. Cannabinoids and levodopa-induced dyskinesia. In: *Levodopa-induced Dyskinesia in Parkinson's Disease* (S. Fox, J. Brotchie, eds.) Springer-Verlag, pp 245 (2014).
77. **Giuffrida A.**, Matricon J. Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. In: *Endocannabinoid regulation of monoamines in psychiatric and neurological disorders* (Van Bocksteale E., ed), Springer. Pp 73-101 (2013).
78. **Giuffrida A.** Academia-industry partnerships as incubators for economic development. *Pharmaceut. Reg. Affairs* 2: 1 (2013).
79. Carta A.R., **Giuffrida A.**, Fisone G. Dyskinesia in Parkinson's disease therapy. In: *Parkinson's Disease Vol 2012*, (AR Carta, A Giuffrida, G Fisone, eds.) Hindawi Publishing Corporation, pp.2 (2012).
80. Fride E., Gobshtis N., Dahan H., Weller A., **Giuffrida A.**, Ben-Shabat S. The endocannabinoid system during development; emphasis on perinatal events and delayed effects. In: *Vitamins & Hormones* (G Litwack ed.), Academic Press (Burlington), 81: 139-158 (2009).
81. Deutch A., **Giuffrida A.**, Roberts J.L. Non-classic signaling in the Brain. In: *From Molecules to Networks: an Introduction to Cellular and Molecular Neuroscience* (JH Byrne & JL Roberts eds.) Elsevier Academic Press (2008).
82. Piomelli D., **Giuffrida A.** Reply: cannabinoid paths to anti-diarrheal drugs. *TiPS* 21: 373 (2000).
83. **Giuffrida A.**, Piomelli D. - Purification and high resolution analysis of anandamide and other fatty acylethanolamides. In: *Lipid Second Messengers* (S.G. Laychock and R.P. Rubin eds.), CRC Press LLC, pp. 113-133 (1998).